Bristol-Myers Squibb stock (US0897961004): $15.2B Hengrui Pharma drug partnership

Bristol-Myers Squibb Company unveiled a major strategic partnership with Hengrui Pharma on May 12, 2026, potentially worth up to $15.2 billion. The deal encompasses 13 early-stage drug programs in oncology, hematology, and immunology. BMS will pay $600 million upfront, with additional milestone payments, according to NJBIZ as of 05/12/2026 and MedCity News as of 05/12/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Bristol-Myers Squibb: core business model

Bristol-Myers Squibb focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company operates in oncology, hematology, immunology, cardiovascular, and neuroscience areas. Its portfolio includes blockbuster drugs like Opdivo for cancer immunotherapy and Eliquis for blood clot prevention, which drive significant revenue for US and global markets.

Headquartered in Princeton, New Jersey, Bristol-Myers Squibb maintains a robust R&D pipeline to address unmet medical needs. The firm invests heavily in biologics and small molecules, partnering with biotech firms to bolster its offerings. This model supports steady growth, particularly relevant for US investors tracking NYSE-listed biopharma leaders.

Main revenue and product drivers for Bristol-Myers Squibb

Key products such as Opdivo generated over $9 billion in global sales for the 12 months ended December 31, 2025, per company filings cited in BMS Investor Relations as of 05/2026. Eliquis and Revlimid remain top contributors, though patent cliffs pose challenges. The Hengrui deal aims to refresh the pipeline with new oncology assets.

Newer launches like Camzyos for heart disease and Sotyktu for immunology are gaining traction in the US market, where Bristol-Myers Squibb derives about 50% of revenue. These drivers underscore the company's exposure to the $500+ billion US pharmaceutical sector.

Details of the Hengrui Pharma partnership

The collaboration includes four oncology/hematology candidates from Hengrui, four immunology assets from BMS, and five joint discovery programs. BMS secures global rights to Hengrui's assets outside China, Hong Kong, and Macau, while Hengrui gains rights there for BMS programs. Hengrui handles early clinical development, with potential co-development options.

BMS payments include $600 million upfront, $175 million on the first anniversary, and another $175 million in 2028, plus up to $15.2 billion in milestones and royalties. Closing is expected in Q3 2026, pending regulatory approval, enhancing BMS's pipeline for US investors.

Industry trends and competitive position

The biopharma sector faces patent expirations but benefits from oncology demand, projected to grow 8% annually through 2030 per IQVIA data published 04/2026. Bristol-Myers Squibb competes with Pfizer, Merck, and Roche, leveraging its immunotherapy leadership. The Hengrui tie-up taps China's innovation hub, diversifying R&D amid US-China biotech tensions.

Why Bristol-Myers Squibb matters for US investors

As a NYSE-listed giant, Bristol-Myers Squibb offers US investors exposure to global drug innovation with heavy reliance on the US healthcare market. Its dividends and buybacks appeal to income seekers, while pipeline deals like Hengrui signal growth potential in a sector vital to the S&P 500.

Conclusion

The Hengrui partnership positions Bristol-Myers Squibb to advance 13 promising programs, potentially bolstering its pipeline amid competitive pressures. With upfront payments and milestone structures, the deal highlights strategic R&D expansion. US investors may note its implications for long-term growth in key therapeutic areas.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.